NFKB1 and B-cell chronic lymphocytic leukemia: The NFκB activation inhibitor counteracted the anti-apoptotic effect of IL-4 in CLL in a dose-dependent manner, especially in ZAP-70 positive patients at 10 μM (Figure 5A).